Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ION-827359 in Healthy Volunteers and Cystic Fibrosis
NCT03647228Phase 1Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Dec 2018
- Primary completion
- Oct 2020
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in cystic fibrosis (CF) comparing IONIS-ENaCRx with Placebo (2 arms). Primary endpoint: Number of Participants with at least one Treatment-Emergent Adverse Event up to 113 Days. Started Dec 2018; status: completed.
02
Drugs
cofirasersen
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03647228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03647228.